Imagyn Medical Technologies of Newport Beach, CA, last month concluded U.S. beta trials for its Site Select breast biopsy device. The company began the trials at 21 sites in September and, with their completion, has begun to market the device. Site
Imagyn Medical Technologies of Newport Beach, CA, last month concluded U.S. beta trials for its Site Select breast biopsy device. The company began the trials at 21 sites in September and, with their completion, has begun to market the device. Site Select allows physicians to locate and extract a biopsy specimen in one step. When the device is used with a stereotactic table, biopsies can be done with local anesthesia on an outpatient basis.
Study Assesses Lung CT-Based AI Models for Predicting Interstitial Lung Abnormality
September 6th 2024A machine-learning-based model demonstrated an 87 percent area under the curve and a 90 percent specificity rate for predicting interstitial lung abnormality on CT scans, according to new research.